Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English (EN)·Polski (PL)·Ukraiński (UK)
Przejdź do strony domowej biblioteki Uniwersytet Ekonomiczny we Wrocławiu Link otwiera się w nowym oknie Logo biblioteki Prolib Integro - strona głównaUniwersytet Ekonomiczny we Wrocławiu

Wyszukujesz frazę ""Antibodies, Neutralizing"" wg kryterium: Temat

  Lista filtrów
Wyrównaj
Wyświetlanie 61-80 z 3942
Tytuł:
Complexing Protein-Free Botulinum Neurotoxin A Formulations: Implications of Excipients for Immunogenicity.
Autorzy:
Martin MU; Independent Researcher, 31832 Springe, Germany.
Frevert J; Merz Therapeutics GmbH, 60318 Frankfurt, Germany.
Tay CM; Merz Asia Pacific Pte., Ltd., Singapore 138567, Singapore.
Pokaż więcej
Źródło:
Toxins [Toxins (Basel)] 2024 Feb 10; Vol. 16 (2). Date of Electronic Publication: 2024 Feb 10.
Typ publikacji:
Journal Article; Review
MeSH Terms:
Botulinum Toxins, Type A*/therapeutic use
Humans ; Excipients ; Polysorbates ; Antibodies, Neutralizing ; Sucrose
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Computational design and engineering of self-assembling multivalent microproteins with therapeutic potential against SARS-CoV-2.
Autorzy:
Qin Q; State Key Laboratory of Genetic Engineering, Shanghai Engineering Research Center of Industrial Microorganisms, MOE Engineering Research Center of Gene Technology, School of Life Sciences, Fudan University, Shanghai, 200438, China.
Jiang X; State Key Laboratory of Genetic Engineering, Shanghai Engineering Research Center of Industrial Microorganisms, MOE Engineering Research Center of Gene Technology, School of Life Sciences, Fudan University, Shanghai, 200438, China.
Huo L; State Key Laboratory of Genetic Engineering, Shanghai Engineering Research Center of Industrial Microorganisms, MOE Engineering Research Center of Gene Technology, School of Life Sciences, Fudan University, Shanghai, 200438, China.
Qian J; State Key Laboratory of Genetic Engineering, Shanghai Engineering Research Center of Industrial Microorganisms, MOE Engineering Research Center of Gene Technology, School of Life Sciences, Fudan University, Shanghai, 200438, China.
Yu H; ACROBiosystems Inc, Beijing, 100176, China.
Zhu H; State Key Laboratory of Genetic Engineering, Shanghai Engineering Research Center of Industrial Microorganisms, MOE Engineering Research Center of Gene Technology, School of Life Sciences, Fudan University, Shanghai, 200438, China.
Du W; State Key Laboratory of Genetic Engineering, Shanghai Engineering Research Center of Industrial Microorganisms, MOE Engineering Research Center of Gene Technology, School of Life Sciences, Fudan University, Shanghai, 200438, China.
Cao Y; ACROBiosystems Inc, Beijing, 100176, China.
Zhang X; ACROBiosystems Inc, Beijing, 100176, China.
Huang Q; State Key Laboratory of Genetic Engineering, Shanghai Engineering Research Center of Industrial Microorganisms, MOE Engineering Research Center of Gene Technology, School of Life Sciences, Fudan University, Shanghai, 200438, China. .; Multiscale Research Institute of Complex Systems, Fudan University, Shanghai, 201203, China. .
Pokaż więcej
Źródło:
Journal of nanobiotechnology [J Nanobiotechnology] 2024 Feb 10; Vol. 22 (1), pp. 58. Date of Electronic Publication: 2024 Feb 10.
Typ publikacji:
Journal Article
MeSH Terms:
COVID-19*
Humans ; Micropeptides ; SARS-CoV-2 ; Binding Sites ; Antibodies, Neutralizing ; Antibodies, Viral
SCR Organism:
SARS-CoV-2 variants
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Oral administration of a recombinant modified RBD antigen of SARS-CoV-2 as a possible immunostimulant for the care of COVID-19.
Autorzy:
Valdez-Cruz NA; Departamento de Biología Molecular y Biotecnología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Cd. Universitaria, Coyoacán, Ciudad de Mexico, México. AP. 70228, CP. 04510, México, D.F, Mexico. .; Centro de Nanociencias y Nanotecnología, Universidad Nacional Autónoma de México, Km 107 Carretera, 22860, Tijuana-Ensenada, Baja California, Mexico. .
Rosiles-Becerril D; Departamento de Biología Molecular y Biotecnología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Cd. Universitaria, Coyoacán, Ciudad de Mexico, México. AP. 70228, CP. 04510, México, D.F, Mexico.
Martínez-Olivares CE; Departamento de Biología Molecular y Biotecnología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Cd. Universitaria, Coyoacán, Ciudad de Mexico, México. AP. 70228, CP. 04510, México, D.F, Mexico.
García-Hernández E; Instituto de Química, Universidad Nacional Autónoma de México, Ciudad Universitaria, 04510, Ciudad de México, Mexico.
Cobos-Marín L; Departamento de Microbiología e Inmunología, Facultad de Medicina Veterinaria y Zootecnia, Universidad Nacional Autónoma de México, Ciudad Universitaria, 04510, Ciudad de México, Mexico.
Garzón D; Unidad de Modelos Biológicos, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Cd. Universitaria, Coyoacán, Ciudad de Mexico, Mexico. AP. 70228, CP. 04510, México, D.F, Mexico.
López-Salas FE; Departamento de Biología Molecular y Biotecnología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Cd. Universitaria, Coyoacán, Ciudad de Mexico, México. AP. 70228, CP. 04510, México, D.F, Mexico.
Zavala G; Unidad de Microscopia Electrónica, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Mor, Mexico.
Luviano A; Departamento de Genética del Desarrollo y Fisiologia Molecular, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Mor, Mexico.
Olvera A; Departamento de Biología Molecular y Bioprocesos, Instituto de Biotecnología, Universidad Nacional Autónoma de México, 62210, Cuernavaca, Mor, Mexico.
Alagón A; Departamento de Biología Molecular y Bioprocesos, Instituto de Biotecnología, Universidad Nacional Autónoma de México, 62210, Cuernavaca, Mor, Mexico.
Ramírez OT; Departamento de Biología Molecular y Bioprocesos, Instituto de Biotecnología, Universidad Nacional Autónoma de México, 62210, Cuernavaca, Mor, Mexico.
Trujillo-Roldán MA; Departamento de Biología Molecular y Biotecnología, Instituto de Investigaciones Biomédicas, Universidad Nacional Autónoma de México, Cd. Universitaria, Coyoacán, Ciudad de Mexico, México. AP. 70228, CP. 04510, México, D.F, Mexico. .; Centro de Nanociencias y Nanotecnología, Universidad Nacional Autónoma de México, Km 107 Carretera, 22860, Tijuana-Ensenada, Baja California, Mexico. .
Pokaż więcej
Źródło:
Microbial cell factories [Microb Cell Fact] 2024 Feb 06; Vol. 23 (1), pp. 41. Date of Electronic Publication: 2024 Feb 06.
Typ publikacji:
Journal Article
MeSH Terms:
SARS-CoV-2*
COVID-19*
Animals ; Humans ; Mice ; Adjuvants, Immunologic ; COVID-19 Vaccines ; Escherichia coli ; Administration, Oral ; Antigens, Viral ; Antibodies, Neutralizing ; Peptides ; Antibodies, Viral
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Novel neutralizing SARS-CoV-2-specific mAbs offer detection of RBD linear epitopes.
Autorzy:
Zadeh SMM; Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran.; Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran.
Bayat AA; Monoclonal Antibody Research Center, Avicenna Research Institute, ACECR, Tehran, Iran.
Shahsavarani H; Laboratory of Regenerative Medicine and Biomedical Innovations, Pasteur Institute of Iran, National Cell Bank, Tehran, Iran.; Department of Cell and Molecular Biology, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University, Tehran, Iran.
Karimi-Busheri F; Department of Oncology, Faculty of Medicine, University of Alberta, Edmonton, AB, T6G 1Z2, Canada.
Kiani J; Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran. .; Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran. .
Ghods R; Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran. .; Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran. .
Madjd Z; Oncopathology Research Center, Iran University of Medical Sciences, Tehran, Iran. .; Department of Molecular Medicine, Faculty of Advanced Technologies in Medicine, Iran University of Medical Sciences, Tehran, Iran. .
Pokaż więcej
Źródło:
Virology journal [Virol J] 2024 Feb 06; Vol. 21 (1), pp. 37. Date of Electronic Publication: 2024 Feb 06.
Typ publikacji:
Journal Article
MeSH Terms:
SARS-CoV-2*
COVID-19*/diagnosis
Animals ; Mice ; Epitopes ; Antibodies, Viral ; Escherichia coli/metabolism ; Antibodies, Neutralizing ; Antibodies, Monoclonal ; Spike Glycoprotein, Coronavirus/chemistry
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Efficacy of H 2 O 2 inactivated bovine virus diarrhoea virus (BVDV) type 1 vaccine in mice.
Autorzy:
Li C; College of Life Sciences, Shihezi University, Shihezi, 832003, Xinjiang, China.
Yu J; College of Life Sciences, Shihezi University, Shihezi, 832003, Xinjiang, China.
Wang Y; College of Life Sciences, Shihezi University, Shihezi, 832003, Xinjiang, China.
Li X; College of Life Sciences, Shihezi University, Shihezi, 832003, Xinjiang, China.
Li Y; College of Life Sciences, Shihezi University, Shihezi, 832003, Xinjiang, China.
An M; College of Life Sciences, Shihezi University, Shihezi, 832003, Xinjiang, China.
Ni W; College of Life Sciences, Shihezi University, Shihezi, 832003, Xinjiang, China. .
Liu K; College of Life Sciences, Shihezi University, Shihezi, 832003, Xinjiang, China.
Hu S; College of Life Sciences, Shihezi University, Shihezi, 832003, Xinjiang, China. .
Pokaż więcej
Źródło:
BMC veterinary research [BMC Vet Res] 2024 Feb 03; Vol. 20 (1), pp. 43. Date of Electronic Publication: 2024 Feb 03.
Typ publikacji:
Journal Article
MeSH Terms:
Bovine Virus Diarrhea-Mucosal Disease*
Cattle Diseases*
Diarrhea Virus 1, Bovine Viral*
Diarrhea Viruses, Bovine Viral*
Viral Vaccines*
Animals ; Cattle ; Mice ; Antibodies, Neutralizing ; Antibodies, Viral ; Diarrhea/veterinary ; Formaldehyde ; Hydrogen Peroxide ; Immunoglobulin G ; Interleukin-4 ; Vaccines, Inactivated
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults ≥60 years of age.
Autorzy:
Curran D; GSK Wavre Belgium.
Matthews S; Freelance c/o GSK Wavre Belgium.
Cabrera ES; GSK Wavre Belgium.
Pérez SN; CAP Centelles Barcelona Spain.
Breva LP; Vaccine Research FISABIO-Public Health Valencia Spain.
Rämet M; Finnish Vaccine Research Tampere Finland.
Helman L; Department of Clinical Medicine George Washington University School of Medicine & Health Sciences Washington District of Columbia USA.
Park DW; Korea University Ansan Hospital Ansan Republic of Korea.
Schwarz TF; Institute of Laboratory Medicine and Vaccination Centre Klinikum Würzburg Mitte Würzburg Germany.
Melendez IMG; Hospital Universitario Fundacion Alcorcon Madrid Spain.
Schaefer A; Medizentrum Essen Borbeck Essen Germany.
Roy N; Medicor Research Greater Sudbury Canada.
Stephan B; SGS proDERM Schenefeld Germany.
Molnar D; GSK Wavre Belgium.
Kostanyan L; GSK Wavre Belgium.
Powers JH 3rd; Department of Clinical Medicine George Washington University School of Medicine & Health Sciences Washington District of Columbia USA.
Hulstrøm V; GSK Wavre Belgium.
Pokaż więcej
Źródło:
Influenza and other respiratory viruses [Influenza Other Respir Viruses] 2024 Feb 03; Vol. 18 (2), pp. e13236. Date of Electronic Publication: 2024 Feb 03 (Print Publication: 2024).
Typ publikacji:
Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article
MeSH Terms:
Respiratory Syncytial Virus Vaccines*/therapeutic use
Respiratory Syncytial Virus Infections*/epidemiology
Respiratory Syncytial Virus Infections*/prevention & control
Respiratory Syncytial Virus, Human*
Respiratory Tract Infections*
Influenza, Human*/prevention & control
Influenza, Human*/drug therapy
Humans ; Aged ; Middle Aged ; Breakthrough Infections ; Viral Fusion Proteins ; Antibodies, Viral ; Antibodies, Neutralizing
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Neutralizing antibody responses to SARS-CoV-2 Omicron variants: Post six months following two-dose & three-dose vaccination of ChAdOx1 nCoV-19 or BBV152.
Autorzy:
Yadav PD; Maximum Containment Laboratory, Pune, Maharashtra, India.
Sardana V; Big Data and Informatics Unit, CSIR-Institute of Genomics & Integrative Biology, New Delhi, India.; Academy of Scientific & Innovative Research, Ghaziabad, Uttar Pradesh, India.
Deshpande GR; Diagnostic Virology Group, Pune, Maharashtra, India.
Shinde PV; Diagnostic Virology Group, Pune, Maharashtra, India.
Thangaraj JWV; Department of Epidemiology & Biostatistics, ICMR-National Institute of Epidemiology, Chennai, Tamil Nadu, India.
George LS; Division of Communicable Diseases, Indian Council of Medical Research, New Delhi, India.
Sapkal GN; ICMR-National Institute of Virology, Pune, Maharashtra, India.
Patil DY; Maximum Containment Laboratory, Pune, Maharashtra, India.
Sahay RR; Maximum Containment Laboratory, Pune, Maharashtra, India.
Shete AM; Maximum Containment Laboratory, Pune, Maharashtra, India.
Joshi M; Department of Science & Technology, Gujarat Biotechnology Research Centre, Gandhinagar, Gujarat, India.
Murhekar M; Department of Epidemiology & Biostatistics, ICMR-National Institute of Epidemiology, Chennai, Tamil Nadu, India.
Godbole S; ICMR-National Institute of Virology, Pune, Maharashtra, India.
Gupta N; Division of Communicable Diseases, Indian Council of Medical Research, New Delhi, India.
Prakash S; Big Data and Informatics Unit, CSIR-Institute of Genomics & Integrative Biology, New Delhi, India.; Academy of Scientific & Innovative Research, Ghaziabad, Uttar Pradesh, India.
Rathore M; Cardiometabolic Disease Unit, CSIR-Institute of Genomics & Integrative Biology, New Delhi, India.; Academy of Scientific & Innovative Research, Ghaziabad, Uttar Pradesh, India.
Ujjainiya R; Cardiometabolic Disease Unit, CSIR-Institute of Genomics & Integrative Biology, New Delhi, India.; Academy of Scientific & Innovative Research, Ghaziabad, Uttar Pradesh, India.
Singh AP; Cardiometabolic Disease Unit, CSIR-Institute of Genomics & Integrative Biology, New Delhi, India.; Academy of Scientific & Innovative Research, Ghaziabad, Uttar Pradesh, India.
Mishra A; Cardiometabolic Disease Unit, CSIR-Institute of Genomics & Integrative Biology, New Delhi, India.; Academy of Scientific & Innovative Research, Ghaziabad, Uttar Pradesh, India.
Dash D; Cardiometabolic Disease Unit, CSIR-Institute of Genomics & Integrative Biology, New Delhi, India.; Academy of Scientific & Innovative Research, Ghaziabad, Uttar Pradesh, India.
Chaudhary K; Big Data and Informatics Unit, CSIR-Institute of Genomics & Integrative Biology, New Delhi, India.; Academy of Scientific & Innovative Research, Ghaziabad, Uttar Pradesh, India.
Sengupta S; Big Data and Informatics Unit, CSIR-Institute of Genomics & Integrative Biology, New Delhi, India.; Academy of Scientific & Innovative Research, Ghaziabad, Uttar Pradesh, India.
Pokaż więcej
Corporate Authors:
ICMR Booster Dose Study Group
Źródło:
The Indian journal of medical research [Indian J Med Res] 2024 Feb 01; Vol. 159 (2), pp. 223-231. Date of Electronic Publication: 2024 Apr 04.
Typ publikacji:
Journal Article
MeSH Terms:
ChAdOx1 nCoV-19*
COVID-19*/prevention & control
COVID-19 Vaccines*
Vaccines, Inactivated*
Humans ; SARS-CoV-2 ; Antibodies, Neutralizing ; Vaccination ; Antibodies, Viral
SCR Organism:
SARS-CoV-2 variants
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Neutralizing monoclonal antibodies against the Gc fusion loop region of Crimean-Congo hemorrhagic fever virus.
Autorzy:
Li L; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.; University of the Chinese Academy of Sciences, Beijing, China.
Chong T; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.; University of the Chinese Academy of Sciences, Beijing, China.
Peng L; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
Liu Y; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
Rao G; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
Fu Y; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
Shu Y; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
Shen J; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
Xiao Q; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
Liu J; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
Li J; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
Deng F; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
Yan B; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
Hu Z; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
Cao S; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.
Wang M; State Key Laboratory of Virology, Wuhan Institute of Virology, Center for Biosafety Mega-Science, Chinese Academy of Sciences, Wuhan, China.; Hubei Jiangxia Laboratory, Wuhan, China.
Pokaż więcej
Źródło:
PLoS pathogens [PLoS Pathog] 2024 Feb 01; Vol. 20 (2), pp. e1011948. Date of Electronic Publication: 2024 Feb 01 (Print Publication: 2024).
Typ publikacji:
Journal Article
MeSH Terms:
Hemorrhagic Fever Virus, Crimean-Congo*/genetics
Hemorrhagic Fever, Crimean*
Animals ; Mice ; Humans ; Antibodies, Monoclonal ; Cryoelectron Microscopy ; Antibodies, Neutralizing ; Epitopes
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Residual Immunity from Smallpox Vaccination and Possible Protection from Mpox, China.
Autorzy:
Huang Y
Guo L
Li Y
Ren L
Nie J
Xu F
Huang T
Zhong J
Fan Z
Zhang Y
Xie Y
Zhang Q
Mei S
Xiao Y
Wang X
Xu L
Guo F
Wang J
Pokaż więcej
Źródło:
Emerging infectious diseases [Emerg Infect Dis] 2024 Feb; Vol. 30 (2), pp. 321-324.
Typ publikacji:
Journal Article
MeSH Terms:
Mpox (monkeypox)*
Smallpox*/prevention & control
Humans ; Vaccination ; Antibodies, Neutralizing ; China/epidemiology ; Vaccinia virus
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknieSzczegóły
Tytuł:
Production of neutralizing antibody fragment variants in the cytoplasm of E. coli for rapid screening: SARS-CoV-2 a case study.
Autorzy:
Tungekar AA; Protein and Structural Biology Research Unit, Faculty of Biochemistry and Molecular Medicine, University of Oulu, 90220, Oulu, Finland.
Recacha R; Protein and Structural Biology Research Unit, Faculty of Biochemistry and Molecular Medicine, University of Oulu, 90220, Oulu, Finland.; Center for Cooperative Research in Biosciences (CIC bioGUNE), Basque Research and Technology Alliance (BRTA), Bizkaia Technology Park, Building 801A, 48160, Derio, Spain.
Ruddock LW; Protein and Structural Biology Research Unit, Faculty of Biochemistry and Molecular Medicine, University of Oulu, 90220, Oulu, Finland. .
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Mar 16; Vol. 13 (1), pp. 4408. Date of Electronic Publication: 2023 Mar 16.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Neutralizing*
COVID-19*
Humans ; SARS-CoV-2 ; Escherichia coli/metabolism ; Antibodies, Viral ; Cytoplasm/metabolism
SCR Organism:
SARS-CoV-2 variants
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Prevalence of Neutralizing Antibodies against Adeno-Associated Virus Serotypes 1, 2, and 9 in Non-Injected Latin American Patients with Heart Failure-ANVIAS Study.
Autorzy:
Sierra-Delgado JA; Centro de Investigaciones, Fundación Cardiovascular de Colombia, Floridablanca 681004, Colombia.; Universidad Industrial de Santander, Bucaramanga 680002, Colombia.
Likhite S; The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205, USA.
Bautista PK; Centro de Investigaciones, Fundación Cardiovascular de Colombia, Floridablanca 681004, Colombia.
Gómez-Ochoa SA; Clínica de Falla Cardíaca y Trasplante, Fundación Cardiovascular de Colombia, Floridablanca 681004, Colombia.
Echeverría LE; Clínica de Falla Cardíaca y Trasplante, Fundación Cardiovascular de Colombia, Floridablanca 681004, Colombia.
Guío E; Centro de Investigaciones, Fundación Cardiovascular de Colombia, Floridablanca 681004, Colombia.
Vargas C; Universidad Industrial de Santander, Bucaramanga 680002, Colombia.
Serrano NC; Centro de Investigaciones, Fundación Cardiovascular de Colombia, Floridablanca 681004, Colombia.
Meyer KC; The Research Institute at Nationwide Children's Hospital, Columbus, OH 43205, USA.; College of Medicine, The Ohio State University, Columbus, OH 43205, USA.
Rincon MY; Centro de Investigaciones, Fundación Cardiovascular de Colombia, Floridablanca 681004, Colombia.
Pokaż więcej
Źródło:
International journal of molecular sciences [Int J Mol Sci] 2023 Mar 14; Vol. 24 (6). Date of Electronic Publication: 2023 Mar 14.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Neutralizing*
Heart Failure*/epidemiology
Humans ; Serogroup ; Latin America ; Antibodies, Viral ; Dependovirus/genetics ; Prevalence ; Genetic Vectors/genetics ; Transduction, Genetic
SCR Organism:
Adeno-associated virus-1
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Use of adjuvant ISA VG 71 to produce neutralizing egg yolk antibodies against bothropic venom.
Autorzy:
Leiva CL; Instituto de Patobiología, Instituto Nacional de Tecnología Agropecuaria, Nicolas Repetto y Los Reseros S/N, Hurlingham, Buenos Aires, Argentina. .; Instituto de Patobiología Veterinaria (IPVET), UEDD INTA-CONICET, Nicolas Repetto y Los Reseros S/N, Hurlingham, Buenos Aires, Argentina. .
Cangelosi A; Centro Nacional de Control de Calidad de Biológicos, ANLIS 'Dr. Carlos G. Malbrán', Av. Vélez Sarsfield, 563, CABA, Argentina.
Mariconda V; Centro Nacional de Control de Calidad de Biológicos, ANLIS 'Dr. Carlos G. Malbrán', Av. Vélez Sarsfield, 563, CABA, Argentina.
Celi A; Instituto de Patobiología, Instituto Nacional de Tecnología Agropecuaria, Nicolas Repetto y Los Reseros S/N, Hurlingham, Buenos Aires, Argentina.; Instituto de Patobiología Veterinaria (IPVET), UEDD INTA-CONICET, Nicolas Repetto y Los Reseros S/N, Hurlingham, Buenos Aires, Argentina.
Joaquim P; Instituto de Patobiología, Instituto Nacional de Tecnología Agropecuaria, Nicolas Repetto y Los Reseros S/N, Hurlingham, Buenos Aires, Argentina.; Instituto de Patobiología Veterinaria (IPVET), UEDD INTA-CONICET, Nicolas Repetto y Los Reseros S/N, Hurlingham, Buenos Aires, Argentina.
Geoghegan P; Centro Nacional de Control de Calidad de Biológicos, ANLIS 'Dr. Carlos G. Malbrán', Av. Vélez Sarsfield, 563, CABA, Argentina.
Fernández-Miyakawa M; Instituto de Patobiología, Instituto Nacional de Tecnología Agropecuaria, Nicolas Repetto y Los Reseros S/N, Hurlingham, Buenos Aires, Argentina.; Instituto de Patobiología Veterinaria (IPVET), UEDD INTA-CONICET, Nicolas Repetto y Los Reseros S/N, Hurlingham, Buenos Aires, Argentina.
Chacana P; Instituto de Patobiología, Instituto Nacional de Tecnología Agropecuaria, Nicolas Repetto y Los Reseros S/N, Hurlingham, Buenos Aires, Argentina.; Instituto de Patobiología Veterinaria (IPVET), UEDD INTA-CONICET, Nicolas Repetto y Los Reseros S/N, Hurlingham, Buenos Aires, Argentina.
Pokaż więcej
Źródło:
Applied microbiology and biotechnology [Appl Microbiol Biotechnol] 2023 Mar; Vol. 107 (5-6), pp. 1947-1957. Date of Electronic Publication: 2023 Feb 01.
Typ publikacji:
Journal Article
MeSH Terms:
Venoms*
Antibodies, Neutralizing*
Mice ; Animals ; Female ; Egg Yolk ; Chickens ; Adjuvants, Immunologic ; Freund's Adjuvant ; Immunoglobulins ; Adjuvants, Pharmaceutic ; Mammals
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Seroprevalence of four endemic human coronaviruses and, reactivity and neutralization capability against SARS-CoV-2 among children in the Philippines.
Autorzy:
Sayama Y; Department of Virology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-Machi, Aoba-Ku, Sendai, Miyagi, 980-8575, Japan. .
Okamoto M; Department of Virology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-Machi, Aoba-Ku, Sendai, Miyagi, 980-8575, Japan.
Saito M; Department of Virology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-Machi, Aoba-Ku, Sendai, Miyagi, 980-8575, Japan.
Saito-Obata M; Department of Virology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-Machi, Aoba-Ku, Sendai, Miyagi, 980-8575, Japan.
Tamaki R; Institute of Tropical Medicine, Nagasaki University, Nagasaki, Japan.
Joboco CD; Biliran Provincial Hospital, Biliran, Philippines.
Lupisan S; Research Institute for Tropical Medicine, Metro Manila, Philippines.
Oshitani H; Department of Virology, Tohoku University Graduate School of Medicine, 2-1 Seiryo-Machi, Aoba-Ku, Sendai, Miyagi, 980-8575, Japan.
Pokaż więcej
Źródło:
Scientific reports [Sci Rep] 2023 Feb 09; Vol. 13 (1), pp. 2310. Date of Electronic Publication: 2023 Feb 09.
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
COVID-19*/epidemiology
COVID-19*/immunology
Coronavirus Infections*/epidemiology
Coronavirus Infections*/immunology
Coronavirus Infections*/virology
Coronavirus*/genetics
Coronavirus*/immunology
Antibodies, Neutralizing*/immunology
Child ; Child, Preschool ; Humans ; Antibodies, Viral ; Coronavirus 229E, Human ; Coronavirus NL63, Human ; Coronavirus OC43, Human ; Philippines/epidemiology ; Recombinant Proteins ; SARS-CoV-2 ; Seroepidemiologic Studies ; Betacoronavirus
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Delivery of a therapeutic antibody to the lower gastrointestinal tract for the treatment of Clostridium difficile infection (CDI).
Autorzy:
Jiang B; Department of Pharmaceutical Sciences, University of Maryland, Baltimore, MD, USA.
Yu D; Department of Pharmaceutical Sciences, University of Maryland, Baltimore, MD, USA.
Zhang Y; Department of Microbial Pathogenesis, University of Maryland, Baltimore, MD, USA.
Hamza T; Department of Microbial Pathogenesis, University of Maryland, Baltimore, MD, USA.
Feng H; Department of Microbial Pathogenesis, University of Maryland, Baltimore, MD, USA.; FZata Inc, Baltimore, MD, USA.
Hoag SW; Department of Pharmaceutical Sciences, University of Maryland, Baltimore, MD, USA.
Pokaż więcej
Źródło:
Pharmaceutical development and technology [Pharm Dev Technol] 2023 Feb; Vol. 28 (2), pp. 232-239. Date of Electronic Publication: 2023 Feb 17.
Typ publikacji:
Journal Article
MeSH Terms:
Antibodies, Neutralizing*/therapeutic use
Clostridium Infections*/drug therapy
Cricetinae ; Mice ; Animals ; Immunoglobulin G ; Colon ; Gastrointestinal Tract
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A single, improbable B cell receptor mutation confers potent neutralization against cytomegalovirus.
Autorzy:
Jenks JA; Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.
Amin S; Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.
Sponholtz MR; Department of Molecular Biosciences, The University of Texas at Austin, Austin, Texas, United States of America.
Kumar A; Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.
Wrapp D; Department of Molecular Biosciences, The University of Texas at Austin, Austin, Texas, United States of America.
Venkatayogi S; Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.
Tu JJ; Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.
Karthigeyan K; Department of Pediatrics, Weill Cornell Medicine, New York, New York, United States of America.
Valencia SM; Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.
Connors M; Department of Pediatrics, Weill Cornell Medicine, New York, New York, United States of America.
Harnois MJ; Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.
Hora B; Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.
Rochat E; Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.
McLellan JS; Department of Molecular Biosciences, The University of Texas at Austin, Austin, Texas, United States of America.
Wiehe K; Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.; Department of Medicine, Duke University School of Medicine, Durham, North Carolina, United States of America.
Permar SR; Duke Human Vaccine Institute, Duke University Medical Center, Durham, North Carolina, United States of America.; Department of Pediatrics, Weill Cornell Medicine, New York, New York, United States of America.
Pokaż więcej
Źródło:
PLoS pathogens [PLoS Pathog] 2023 Jan 20; Vol. 19 (1), pp. e1011107. Date of Electronic Publication: 2023 Jan 20 (Print Publication: 2023).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Neutralizing*/genetics
Antibodies, Neutralizing*/immunology
Antibodies, Viral*/genetics
Antibodies, Viral*/immunology
Cytomegalovirus*/genetics
Cytomegalovirus*/immunology
Cytomegalovirus Infections*/genetics
Cytomegalovirus Infections*/immunology
Cytomegalovirus Vaccines*/therapeutic use
Humans ; Mutation ; Receptors, Antigen, B-Cell/genetics ; Receptors, Antigen, B-Cell/immunology ; Viral Envelope Proteins/genetics ; Viral Envelope Proteins/immunology
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Effectiveness of Sotrovimab in the Omicron Storm Time: A Case Series.
Autorzy:
Cicchitto G; COVID-19 Hospital 'M. Scarlato', Department of Pneumology, 84018 Salerno, Italy.
Cardillo L; Istituto Zooprofilattico Sperimentale del Mezzogiorno, Via Salute 2, 80055 Naples, Italy.
Sequino D; Department of Clinical Medicine and Surgery, Section of Respiratory Disease Federico II University Hospital, 80055 Naples, Italy.
Sabatini P; Umberto I' Hospital, Unit of Virology and Microbiology, Nocera Inferiore, 84018 Salerno, Italy.
Adamo L; Umberto I' Hospital, Unit of Virology and Microbiology, Nocera Inferiore, 84018 Salerno, Italy.
Marchitiello R; COVID-19 Hospital 'M. Scarlato', Unit of Clinical Pathology Laboratory, 84018 Salerno, Italy.
Viscardi M; Istituto Zooprofilattico Sperimentale del Mezzogiorno, Via Salute 2, 80055 Naples, Italy.
Cozzolino L; Istituto Zooprofilattico Sperimentale del Mezzogiorno, Via Salute 2, 80055 Naples, Italy.
Cavallera A; COVID-19 Hospital 'M. Scarlato', Department of Radiology, 84018 Salerno, Italy.
Bocchino M; Department of Clinical Medicine and Surgery, Section of Respiratory Disease Federico II University Hospital, 80055 Naples, Italy.
Sanduzzi Zamparelli A; Department of Clinical Medicine and Surgery, Section of Respiratory Disease Federico II University Hospital, 80055 Naples, Italy.
Ferrigno F; COVID-19 Hospital 'M. Scarlato', Department of Pneumology, 84018 Salerno, Italy.
de Carlo E; Istituto Zooprofilattico Sperimentale del Mezzogiorno, Via Salute 2, 80055 Naples, Italy.
de Martinis C; Istituto Zooprofilattico Sperimentale del Mezzogiorno, Via Salute 2, 80055 Naples, Italy.
Fusco G; Istituto Zooprofilattico Sperimentale del Mezzogiorno, Via Salute 2, 80055 Naples, Italy.
Pokaż więcej
Źródło:
Viruses [Viruses] 2022 Dec 30; Vol. 15 (1). Date of Electronic Publication: 2022 Dec 30.
Typ publikacji:
Observational Study; Journal Article
MeSH Terms:
Antibodies, Monoclonal, Humanized*/therapeutic use
Antibodies, Neutralizing*/therapeutic use
COVID-19*/therapy
Humans ; Antibodies, Viral ; SARS-CoV-2 ; Spike Glycoprotein, Coronavirus
SCR Organism:
SARS-CoV-2 variants
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
A broadly neutralizing monoclonal antibody overcomes the mutational landscape of emerging SARS-CoV-2 variants of concern.
Autorzy:
Parray HA; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Narayanan N; Regional Centre for Biotechnology, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Garg S; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Rizvi ZA; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Shrivastava T; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Kushwaha S; National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi, India.
Singh J; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Murugavelu P; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Anantharaj A; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Mehdi F; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Raj N; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Singh S; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Dandotiya J; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Lukose A; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Jamwal D; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Kumar S; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Chiranjivi AK; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Dhyani S; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Mishra N; Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
Kumar S; ICGEB-Emory Vaccine Center, International Centre for Genetic Engineering and Biotechnology, New Delhi, India.
Jakhar K; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Sonar S; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Panchal AK; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Tripathy MR; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Chowdhury SR; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Ahmed S; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Samal S; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Mani S; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Bhattacharyya S; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Das S; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Sinha S; Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
Luthra K; Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India.
Batra G; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Sehgal D; National Institute of Immunology, Aruna Asaf Ali Marg, New Delhi, India.
Medigeshi GR; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Sharma C; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Awasthi A; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Garg PK; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Nair DT; Regional Centre for Biotechnology, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Kumar R; Translational Health Science and Technology Institute, NCR Biotech Science Cluster, Faridabad, Haryana, India.
Pokaż więcej
Źródło:
PLoS pathogens [PLoS Pathog] 2022 Dec 12; Vol. 18 (12), pp. e1010994. Date of Electronic Publication: 2022 Dec 12 (Print Publication: 2022).
Typ publikacji:
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms:
Angiotensin-Converting Enzyme 2*/chemistry
Antibodies, Neutralizing*/therapeutic use
COVID-19*/immunology
COVID-19*/therapy
SARS-CoV-2*/genetics
SARS-CoV-2*/immunology
Animals ; Humans ; Mice ; Antibodies, Monoclonal/therapeutic use ; Antibodies, Viral/therapeutic use ; Mice, Transgenic ; Neutralization Tests ; Spike Glycoprotein, Coronavirus/genetics
SCR Organism:
SARS-CoV-2 variants
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Computational epitope mapping of class I fusion proteins using low complexity supervised learning methods.
Autorzy:
Fischer MFS; Department of Chemistry, Vanderbilt University, Nashville, Tennessee, United States of America.; Center for Structural Biology, Vanderbilt University, Nashville, Tennessee, United States of America.
Crowe JE; Vanderbilt Vaccine Center, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.; Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.; Department of Pathology, Microbiology and Immunology, Vanderbilt University Medical Center, Nashville, Tennessee, United States of America.
Meiler J; Department of Chemistry, Vanderbilt University, Nashville, Tennessee, United States of America.; Center for Structural Biology, Vanderbilt University, Nashville, Tennessee, United States of America.; Institute for Drug Discovery, Leipzig University Medical School, Leipzig, Saxony, Germany.
Pokaż więcej
Źródło:
PLoS computational biology [PLoS Comput Biol] 2022 Dec 07; Vol. 18 (12), pp. e1010230. Date of Electronic Publication: 2022 Dec 07 (Print Publication: 2022).
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural
MeSH Terms:
Antibodies, Monoclonal*
Antibodies, Neutralizing*
Epitope Mapping/methods ; Cryoelectron Microscopy ; Epitopes ; Supervised Machine Learning ; Antibodies, Viral
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Tytuł:
Imprinted antibody responses against SARS-CoV-2 Omicron sublineages.
Autorzy:
Park YJ; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA.
Pinto D; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Walls AC; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA.
Liu Z; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.
De Marco A; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Benigni F; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Zatta F; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Silacci-Fregni C; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Bassi J; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Sprouse KR; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Addetia A; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Bowen JE; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Stewart C; Department of Biochemistry, University of Washington, Seattle, WA, USA.
Giurdanella M; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Saliba C; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Guarino B; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Schmid MA; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Franko NM; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
Logue JK; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
Dang HV; Vir Biotechnology, San Francisco, CA, USA.
Hauser K; Vir Biotechnology, San Francisco, CA, USA.
di Iulio J; Vir Biotechnology, San Francisco, CA, USA.
Rivera W; Vir Biotechnology, San Francisco, CA, USA.
Schnell G; Vir Biotechnology, San Francisco, CA, USA.
Rajesh A; Vir Biotechnology, San Francisco, CA, USA.
Zhou J; Vir Biotechnology, San Francisco, CA, USA.
Farhat N; Vir Biotechnology, San Francisco, CA, USA.
Kaiser H; Vir Biotechnology, San Francisco, CA, USA.
Montiel-Ruiz M; Vir Biotechnology, San Francisco, CA, USA.
Noack J; Vir Biotechnology, San Francisco, CA, USA.
Lempp FA; Vir Biotechnology, San Francisco, CA, USA.
Janer J; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.
Abdelnabi R; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium.
Maes P; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium.
Ferrari P; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.; Division of Nephrology, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Clinical School, University of New South Wales, Sydney, New South Wales, Australia.
Ceschi A; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.; Clinical Trial Unit, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Division of Clinical Pharmacology and Toxicology, Institute of Pharmacological Sciences of Southern Switzerland, Ente Ospedaliero Cantonale, Lugano, Switzerland.; Department of Clinical Pharmacology and Toxicology, University Hospital Zurich, Zurich, Switzerland.
Giannini O; Faculty of Biomedical Sciences, Università della Svizzera italiana, Lugano, Switzerland.; Department of Medicine, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
de Melo GD; Institut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, F-75015 Paris, France.
Kergoat L; Institut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, F-75015 Paris, France.
Bourhy H; Institut Pasteur, Université Paris Cité, Lyssavirus Epidemiology and Neuropathology Unit, F-75015 Paris, France.
Neyts J; KU Leuven Department of Microbiology, Immunology and Transplantation, Rega Institute for Medical Research, Laboratory of Virology and Chemotherapy, B-3000 Leuven, Belgium.
Soriaga L; Vir Biotechnology, San Francisco, CA, USA.
Purcell LA; Vir Biotechnology, San Francisco, CA, USA.
Snell G; Vir Biotechnology, San Francisco, CA, USA.
Whelan SPJ; Department of Molecular Microbiology, Washington University School of Medicine, St. Louis, MO, USA.
Lanzavecchia A; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Virgin HW; Vir Biotechnology, San Francisco, CA, USA.; Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, MO, USA.; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.
Piccoli L; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Chu HY; Division of Allergy and Infectious Diseases, University of Washington, Seattle, WA, USA.
Pizzuto MS; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Corti D; Humabs Biomed SA, Subsidiary of Vir Biotechnology, Bellinzona, Switzerland.
Veesler D; Department of Biochemistry, University of Washington, Seattle, WA, USA.; Howard Hughes Medical Institute, University of Washington, Seattle, WA, USA.
Pokaż więcej
Źródło:
Science (New York, N.Y.) [Science] 2022 Nov 11; Vol. 378 (6620), pp. 619-627. Date of Electronic Publication: 2022 Oct 20.
Typ publikacji:
Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
MeSH Terms:
Antibodies, Neutralizing*/immunology
Antibodies, Viral*/immunology
Antibody Formation*
COVID-19*/immunology
SARS-CoV-2*/genetics
SARS-CoV-2*/immunology
Spike Glycoprotein, Coronavirus*
Immune Evasion*
Humans ; Neutralization Tests ; Immunologic Memory ; Memory B Cells/immunology
SCR Organism:
SARS-CoV-2 variants
Czasopismo naukowe
Pełny tekst  Link otwiera się w nowym oknie Pełny tekstSzczegóły
Wyświetlanie 61-80 z 3942

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies